



Date: Dec 3, 2008

To whom it may concern.

Protocol No: CERE-120-06

Study Title: A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputamin (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson's Disease.

EudraCT No.: 2007-006721-27


RE: WITHDRAWAL OF CLINICAL TRIAL APPLICATION

Ceregene, the sponsor of this trial, has just completed the initial analysis from a Phase 2, Double-Blind, Placebo-Controlled study of CERE-120 conducted in the US. This study, CERE-120-02, did not demonstrate an appreciable difference in efficacy between patients treated with CERE-120 versus those in the control group. Both groups showed an approximate 7 point improvement in the primary efficacy endpoint, the Unified Parkinson's Disease Rating Scale, Motor Subscale, Off Condition, at 12 months. CERE-120 was generally safe and well-tolerated in this study.

Therefore, Ceregene does not plan to proceed with the CERE-120-06 protocol in Europe as it is currently designed and hereby withdraws the Clinical Trial Application to conduct this study. The reason for this withdrawal is not related to clinical safety.

We trust that this information will be sufficient. Ceregene, Inc. would like to thank you for your time spent on this application.

Sincerely,



Director, Clinical Operations
Ceregene, Inc.